SWX:ROG
SWX:ROGPharmaceuticals

Will FDA’s Rapid-Delivery Lunsumio VELO Approval Reshape Roche Holding's (SWX:ROG) High-Value Biologics Narrative?

Earlier this month, Genentech, a member of the Roche Group, received U.S. FDA accelerated approval for Lunsumio VELO, a subcutaneous formulation of mosunetuzumab for adults with relapsed or refractory follicular lymphoma after at least two prior systemic therapies, cutting administration time from hours to about one minute. This approval not only broadens Roche’s oncology offering but also highlights how treatment convenience and clinic efficiency are becoming core differentiators in cancer...
SWX:ABBN
SWX:ABBNElectrical

Assessing ABB (SWX:ABBN) Valuation After New Canadian Space Agency ALExIS Spectrometer Contract

ABB (SWX:ABBN) just landed a new contract with the Canadian Space Agency to design the ALExIS infrared spectrometer for Canada’s upcoming lunar rover, putting its space instrumentation credentials firmly in the spotlight for investors. See our latest analysis for ABB. The ALExIS win comes on top of a solid run, with ABB’s share price up meaningfully this year and a strong multi year total shareholder return suggesting momentum is still building rather than fading. If this space contract has...
SWX:SGKN
SWX:SGKNBanks

Top European Dividend Stocks To Consider In December 2025

As European markets experience a boost from steady economic growth and looser monetary policy, the pan-European STOXX Europe 600 Index has ended the week 1.60% higher, with major stock indexes also showing gains. In this environment of cautious optimism, dividend stocks can offer investors a reliable income stream and potential for capital appreciation, making them an attractive option in today's market conditions.
SWX:ALC
SWX:ALCMedical Equipment

Alcon (SWX:ALC): Reassessing Valuation After Recent Share Price Stabilisation

Alcon (SWX:ALC) has quietly outperformed the broader healthcare space over the past month, with shares climbing about 4% even as the stock remains down sharply year to date. See our latest analysis for Alcon. That recent 30 day share price return of 3.84% looks more like a stabilisation than a full reversal. The year to date share price is still down 16.42%, and the one year total shareholder return is negative but modestly positive over three years. If Alcon’s move has you reassessing the...
SWX:CLN
SWX:CLNChemicals

Clariant (SWX:CLN): Assessing Valuation After a Steep Share Price Drop and Ongoing Earnings Growth

Clariant (SWX:CLN) has been grinding through a tricky stretch, with the share price down sharply this year even as revenue and net income inch higher. That disconnect is what matters for investors now. See our latest analysis for Clariant. With the share price now around CHF 7.12, a steep year to date share price loss contrasts with modest revenue and earnings growth. This suggests sentiment is still catching up to fundamentals and that momentum remains fragile rather than firmly...
SWX:UBSG
SWX:UBSGCapital Markets

Is UBS Group (SWX:UBSG) Turning Job Cuts And Tech Centralization Into A Sharper Efficiency Story?

UBS Group AG recently outlined further Credit Suisse integration steps, including multi-wave job cuts through 2026 and leadership changes in operations and technology, with Group Technology set to report to incoming Group Chief Operating Officer Beatriz Martin from January 2026. By consolidating technology under the Group COO and emphasizing artificial intelligence and IT migration, UBS is signaling a push to streamline operations while completing the complex Credit Suisse integration. We’ll...